STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models
STX-721 是一种共价 EGFR/HER2 外显子 20 抑制剂,它利用外显子 20 突变体的动态蛋白状态,并在人类癌症模型中实现了独特的突变选择性。
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-24-3833
Raymond A Pagliarini,Jack A Henderson,Benjamin C Milgram,Deanna R Borrelli,Natasja Brooijmans,Brendan J Hilbert,Michael R Huff,Takahiro Ito,Gregory V Kryukov,Brendon Ladd,Brent R Martin,Hashim Motiwala,Erin O'Hearn,Chia-Feng Tsai,Weixue Wang,Justine Bellier,Luke Boland,Sarah Clark,Emily Hensley,Aaron N Hata,Petr Kuzmic,Angel Guzman-Perez,Erica L Jackson,Darrin D Stuart